Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07763457
Starting soon Observational

Japanese Strabismus Outcomes Assessment and Research Group Study

NCT07763457 · tracked via the Priya Life Science Japan tracker
Sponsor
Kyoto University, Graduate School of Medicine
Phase
Observational
Started
2026-09
Last updated
2026-08-13

Condition(s) studied

Strabismus

Investigational drug(s) / intervention(s)

Strabismus SurgeryConservative Treatment or Observation

Strabismus Surgery: Surgical correction of ocular deviation.

Conservative Treatment or Observation: Non-surgical management, including clinical observation for natural history, prism therapy, or orthoptic treatment.

Study summary

This retrospective study constructs the largest multicenter registry of strabismus care in Japan. The registry evaluates real-world surgical and conservative treatment outcomes, safety, and natural history for various types of strabismus, including common, rare, and complex cases.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with strabismus who underwent clinical evaluation or management (including observation for natural history, conservative treatment, or surgery) at participating institutions. * Observation period for common strabismus: A restricted recent timeframe (e.g., the most recent 3 years) to minimize selection bias. * Observation period for rare and complex strabismus: Up to 10 years (January 1, 2016, to the date of Institutional Review Board approval) to secure an adequate sample size. Exclusion Criteria: * Patients who formally opted out of data utilization for this study.

Primary outcome measure(s)

  • Success rate of ocular deviation correction and residual deviation angle — At standard observation intervals (2 to 4 weeks, 3 to 6 months, 1 year, and 2 years post-treatment or baseline) and through study completion, up to 10 years.
    Assess the angle of ocular deviation and determine the success rate of clinical management (including observation for natural history, surgical, or conservative treatments) based on established clinical criteria.

Trial sites (1)

FacilityCityRegionStatus
Kyoto University Graduate School of Medicine Kyoto Kyoto

More Kyoto University, Graduate School of Medicine trials in Japan

A Computer Game for Postpartum Mental Health After Emergency Cesarean Birth Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07763457 on ClinicalTrials.gov ↗ ← All trials in Japan